SAFETY ALERT: Guidance Issued for Recall on Polymyxin B and Vecuronium
Bedford Laboratories has issued guidance on its voluntary recall, originally announced on August 2, 2011, after visible glass particles were found in a few vials of the following products:
• Polymyxin B for Injection USP, 500,000 Units per vial, NDC 55390-0139-10, Lot Numbers 1942980 (exp. August 2013), 1895027 (exp. Jun 2013)
• Vecuronium Bromide for Injection, 10 mg per vial, NDC 55390-0037-10, Lot Number 1865067 (exp. May 2012)
• Vecuronium Bromide for Injection, 20 mg per vial, NDC 55390-0039-10, Lot Number 1865069 (exp. February 2012)
Injections contaminated with particles can be harmful when injected into the bloodstream. Healthcare professionals should not use these product lots and should quarantine them immediately for return. There have been no reported adverse events from using the recalled medication lots to date. Healthcare providers and patients can report adverse events to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.For more information, call (440) 232-3320, or visit www.bedfordlabs.com.